Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Separate neuronal pathways mediate social, attentional behaviors
Here is a roundup of autism-related news and research spotted around the web for the week of 20 July.
Separate neuronal pathways mediate social, attentional behaviors
Here is a roundup of autism-related news and research spotted around the web for the week of 20 July.
In memoriam: Susumu Tonegawa, ‘intellectual giant’
He won the Nobel Prize for his work on immunology and then went on to define the field of learning and memory.
In memoriam: Susumu Tonegawa, ‘intellectual giant’
He won the Nobel Prize for his work on immunology and then went on to define the field of learning and memory.